Abstract
Introduction:
Nanomedicines can improve drug delivery and efficacy while reducing side effects. Our study examines the impact of a nano-formulation of Sparstolonin B (nSsnB), a TLR-4 antagonist, on LPS-induced inflammation in RAW264.7 cells and lung injury in mice.
Methods:
RAW264.7 cells were treated with LPS (1 μg/mL) ± nSsnB (2–64 μg/mL) for 24 h. Cell viability was assessed, cytokine levels in media were measured, and cell lysates were used to quantify NF-κB activation. C57BL/6 mice were treated with prophylactic intratracheal (IT) nSsnB (0.625 mg/kg) ± IT LPS (2.5 mg/kg). Blood and BALF were collected for cytokine, protein and cytological analysis. Lung histology was scored to evaluate lung injury. The relative abundance of MyD88 and phosphorylated NF-κB were measured in lung and HLL mice were used to measure NF-κB activation in vivo.
Results:
nSsnB demonstrated reduced toxicity vs. free SsnB. nSsnB ameliorated the LPS-induced increase in TNF-α, IL-6 and NF-κB P65 phosphorylation in RAW264.7 cells. LPS-treated mice revealed histologic ALI, elevated BALF neutrophils/macrophages/total protein, and increased levels of TNF-α/IL-6 in both BALF and plasma. Prophylactic nSsnB attenuated all these parameters in the LPS/nSsnB group. The increased levels of MyD88 and P-NF-κB P65 in lung from LPS-treated mice were reduced in the LPS/nSsnB group and nSsnB attenuated the increase in NF-κB activation induced by IT LPS in HLL mice.
Conclusion:
nSsnB demonstrates less toxicity than free SsnB and attenuates the effects of LPS on inflammation in RAW264.7 cells. Prophylactic nSsnB attenuates LPS-induced ALI by reducing inflammation via MyD88/NF-κB signaling pathways. Collectively these findings support the therapeutic potential of nano-formulated nSsnB for ALI treatment.
1 Introduction
Acute respiratory distress syndrome (ARDS), a severe form of acute lung injury (ALI) (Arora et al., ), is characterized by widespread inflammation and damage to the alveolar-capillary barrier, leading to severe hypoxemia and respiratory failure. Current treatments for ARDS include mechanical ventilation to maintain oxygenation and supportive care like fluid resuscitation/vasopressors to maintain blood pressure, nutrition support and renal replacement therapy in severe cases (). While supportive care can provide life support, it does not address the underlying causes, and thus, does not completely prevent the complications of ARDS. Additionally, treatments such as mechanical ventilation and fluid management carry risks of complications. Medications such as corticosteroids, antibiotics, nitric oxide (Jiang et al.), and nonsteroidal anti-inflammatory drugs have been used in the treatment of ALI/ARDS, but their efficacy varies (; ; ). There are currently no specific drugs on the market for treating ALI/ARDS, and the efficacy and safety of existing treatments requires further validation (). Moreover, research on drugs specifically targeting ALI/ARDS is relatively limited (), necessitating more clinical trials to assess their efficacy. Conceptually, therapies to target exaggerated systemic inflammation in ARDS could help to reduce injury to the lungs and other organs.
Toll-like receptors (TLRs) are a group of transmembrane proteins crucial for recognizing pathogenic threats and initiating an innate immune response (). Given the continuous exposure of the lungs to various infectious agents, antigens, and host-derived danger signals, stromal and myeloid cells in the lung express a variety of TLRs (). These receptors detect both endogenously derived damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs), activating TLR-associated signaling pathways essential for host defense (). Consequently, TLRs play a critical role in activating host defense mechanisms during microbial infections as well as non-infectious pulmonary disorders like interstitial lung disease and asthma (). In particular, TLRs are vital for immune host defense against bacterial, fungal, and viral pathogens in the lungs (; ; ; ; ). Specifically, TLR4 is implicated in inflammatory conditions, suggesting the potential for disease management through TLR-targeted immunotherapeutic approaches (). In the lung injury, TLR signaling also plays a key role in the pathogenesis of diseases such as ARDS, chronic obstructive pulmonary disease (COPD), and pneumonia. Overactivation of TLRs can lead to excessive inflammation, contributing to tissue damage and worsening disease outcomes (; ). Studies have shown that TLR4 antagonists can reduce inflammation and protect against lung injury in models of sepsis and acute lung injury (; ). TLR signaling is mediated through the adaptor proteins MyD88, which trigger downstream inflammatory responses. Recent studies have shown that targeting these adaptors can attenuate TLR-induced lung injury. Inhibition of MyD88 signaling has been shown to reduce inflammation and improve recovery in animal models of LPS-induced lung injury (). Several studies have indicated that altering TLR signaling to dampen inflammation could serve as an effective strategy for mitigating ALI/ARDS ().
Sparstolonin B (SsnB) is a potent TLR-4 antagonist, that shows promise as a pharmacological therapy in inflammatory conditions (). Despite its potency as a TLR-4 antagonist, SsnB’s flat aromatic structure and poor aqueous solubility leads to significantly reduced drug bioavailability (). One study shows the absolute bioavailability of SsnB is only approximately 7% (), thus restricting its therapeutic applications. The current study uses a nano-formulation of SsnB (nSsnB) formulated with a linear PEGylated dendritic telodendrimer PEG5kCA4Rf4 to increase SsnB solubility and bioavailability. Our results provide evidence that nSsnB is less toxic and can ameliorate inflammation in LPS-treated RAW264.7 cells. Prophylactic intratracheal (IT) nSsnB also attenuates systemic inflammation and lung injury in ALI mouse model induced by the IT LPS administration. Our results also provide evidence that nSsnB downregulates inflammation and improves lung injury by inhibiting pulmonary MyD88/NF-κB activation.
2 Materials and methods
2.1 The development of SsnB nano-formulation
The telodendrimer PEG5kCA4Rf4 was used to encapsulate SsnB. For nomenclature, PEG5k represents a polyethylene glycol with a molecular weight of 5 kDa and CA4Rf4 indicates that four cholic acids and riboflavin molecules were conjugated on α-amino and ε-amino groups respectively on the periphery of dendritic polylysine. PEG5kCA4Rf4 was prepared following our previous procedure via peptide chemistry (; ). SsnB was encapsulated within a telodendrimer (TD) nanocarrier, PEG5kCA4Rf4, using a thin-film hydration method as previously described (; ). Briefly, SsnB solution in DMSO was added into TD solution in CHCl3/MeOH (10:1 v/v) mixture at a TD/SsnB weight ratio of 10:1 (w/w). The solvents were evaporated on a Rota evaporator, resulting in a thin, homogeneous film of SsnB-TD mixture coated on the flask wall. The film was further dried under high vacuum for 1 h. Subsequently, the film was hydrated in PBS. The particle size distributions of the drug-loaded nanoparticles (NPs) were determined using dynamic light scattering (DLS) Zetasizer (Malvern).
2.2 Cell culture and effect of SsnB on cell viability and inflammation in RAW264.7 cells
The RAW264.7 macrophage cell line was obtained from American Type Culture Collection (Rockville, MA). Cells were maintained in Dulbecco’s Modified Eagle’s Medium (Gibco, Gaithersburg, MD) and supplemented with 10% fetal bovine serum (Atlanta Biologicals, Flowery Branch, GA), 1 mM sodium pyruvate (Gibco) and 100 U/mL penicillin G and 100 μg/mL streptomycin at 37°C in a humidified incubator with 5% CO2 (; ). The growth medium was refreshed every other day. A phase contrast microscope was used to monitor the RAW264.7 cells daily.
For cell viability study, Raw264.7 cells were seeded in a 96-well plate with the cell density of 4 × 103 cells per well. After an overnight incubation, the cells were treated with different concentrations of free SsnB or nSsnB, and blank TD. After 72 h incubation, Cell titer 96 aqueous cell proliferation reagent, which is composed of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium (MTS, Cat. #: G3582, Promega) and an electron-coupling reagent phenazine methosulphate (PMS), was added to each well according to the manufacturer’s instructions and further incubated for 1–4 h at 37°C. The cell viability was determined by measuring the absorbance at 490 nm using a microplate reader (BioTek Synergy H1). Untreated cells served as a control. Results were shown as the average cell viability of triplicate wells via an equation: Cell viability % = [(ODtreat-ODblank)/(ODcontrol-ODblank) × 100%].
For examining the effect of nSsnB on inflammation, RAW264.7 6-well plate with the cell density of 3 × 105 cells per well. After an overnight incubation, the cells were treated with LPS (1 μg/mL) ± nSsnB (32 μg/mL) for 24 h. The culture medium and cells were collected for detection of inflammatory cytokines and protein analysis, respectively.
2.3 Hemolytic assays
Fresh blood was obtained from a healthy human volunteer and mixed with a PBS solution containing 20 mM EDTA. Red blood cells (RBCs) were then isolated by centrifugation at 1,000 rpm for 10 min. Subsequently, the RBCs were washed three times with PBS and resuspended in PBS (; ; ). Free SsnB or nSsnB were added to 200 µL of RBC solutions at concentrations of 10, 100, and 200 μg/mL, followed by gentle mixing and incubation at 37°C for 30 min, 4 h, and overnight, respectively. Afterward, the samples were centrifuged at 1,000 rpm for 5 min, and the hemoglobin in the supernatant was measured using a NanoDrop spectrophotometer at 540 nm. PBS and Triton X-100 (2%) were included as negative and positive controls, respectively, by incubating them with RBCs. Hemolytic toxicity was determined using the following equation: Hemolysis% = [(ODsample - ODPBS)/(ODtriton - ODPBS)] × 100%.
2.4 Animals and lung injury model
Male and female C57BL/6 and HIV-LTR/Luciferase (HLL) mice, aged 8 weeks, were purchased from Jackson Laboratories (Bar Harbor, ME). The mice were housed in a controlled environment with a temperature of 22°C and a photoperiod of 12 h light and 12 h dark, with ad libitum access to food and water. All animal procedures were approved by the Institutional Animal Care and Use Committee of SUNY Upstate Medical University (IACUC #344 and #437) and conducted in compliance with the National Institutes of Health and ARRIVE guidelines for the use of laboratory animals.
2.5 LPS-induced lung injury, nSsnB treatment and tissue harvest
All mice received non-invasive tracheal instillation using an aerosolizer with nSsnB (0.625 mg/kg) or vehicle 2 h prior to inducing lung injury with LPS (2.5 mg/kg) or saline, as previously described (; ). Briefly, mice in the septic and control groups were anesthetized via intraperitoneal injection of a combination of ketamine (80 mg/kg) and xylazine (8 mg/kg). After induction of anesthesia, mice were positioned in the supine position on an intubating platform, with their incisors suspended and a fiber-optic illuminator positioned over the trachea. Tongue retraction and upward-leftward positioning were performed using forceps to visualize the larynx, aided by hands-free binocular magnifiers. The MicroSprayer Aerosolizer (Cat. #: YAN30012, Shanghai Yuyan Instruments Co., Ltd.) was then inserted into the tracheal lumen, and LPS, nSsnB, and saline solution (not exceeding a volume of 70 µL per mouse) were instilled. Mice were maintained in the same position on the intubating platform for at least 30 s before being placed prone on a heating pad for recovery. All surviving mice were euthanized under anesthesia at 24 h post-LPS administration, and blood (in EDTA), lung tissue (fixed with 10% formalin for histology and frozen for protein analysis), and bronchoalveolar lavage fluid (BALF) were collected. The IT administration of LPS (2.5 mg/kg) in this study did not result in mortality among any of the experimental groups.
2.6 Cytological and protein analysis in BALF
BALF was collected from the mouse lung and lavaged with three aliquots of 0.5 mL sterile saline, followed by centrifugation at 250 × g for 10 min. The resulting pellet was resuspended in 1 mL of sterile saline. A 100 µL portion of the cell suspension was then centrifuged using a cytospin centrifuge (Hettich ROTOFIX 32A) at 1,000 rpm for 3 min to adhere the cells to a slide (). The slide was air-dried and stained with Hema-3 (Cat. #: 23-122929, 23-122937, 23-122952, Fisher Scientific, Kalamazoo, MI) for subsequent analysis. Neutrophils and macrophages were quantified in 20 high-power fields (HPF) by blinded reviewers utilizing a Nikon Eclipse TE2000-U research microscope (Nikon, Melville, NY). Protein concentration in BALF was measured using the BCA micro assay kit from Thermo Scientific (Cat. #: 23235) according to the provided guidelines.
2.7 Western blot and ELISA
Lung tissue was homogenized in RIPA buffer, and the extracted protein was utilized for Western blot analysis (). A total of 20 µg of protein was separated by SDS-PAGE gel electrophoresis, followed by transfer to PVDF membranes (Cat. #: IPVH00010, Millipore Co., Ltd. United States). The membranes were blocked with 5% non-fat milk (Cat. #: 1706404XTU, Bio-Rad Laboratories) in Tris-buffered saline plus 0.5% Tween-20 (TBS-T) from Fisher Scientific (Cat. #: BP337-500) for 1 h at room temperature, and then incubated overnight at 4°C with primary antibodies purchased from Santa Cruz Biotechnology, including MyD88 (Cat. #: sc-74532, 1:200 dilution) and phosphorylated-NF-κB (p65) (Cat. #: sc-136548, 1:200 dilution). Subsequently, the membranes were probed with a secondary antibody conjugated to horseradish peroxidase (HRP) obtained from Santa Cruz Biotechnology (Cat. #: 516102, 1:1,000 dilution) for 1 h at room temperature. Antibody-antigen complexes were visualized using enhanced chemiluminescence (ECL, Cat. #: 34580, Thermo Scientific) according to the manufacturer’s instructions. Quantitative analysis of the immunoreactive bands was performed using densitometry with ImageJ software, and the relative density of the bands was normalized to the density of the corresponding β-actin bands.
Blood samples, BALF and lung tissue were collected to measure levels of TNF-α (Cat. #: 50-112-8800, Invitrogen) and IL-6 (Cat. #: 50-112-8863, Invitrogen) by ELISA. Serum from blood and BALF were used directly for ELISA following appropriate dilution. Lung tissue required homogenization in protein lysis buffer (RIPA) to extract the supernatant, followed by protein concentration measurement using a BCA assay. The protein solution then was diluted to a final concentration of 1 mg/mL before ELISA analysis. All cytokines were quantified using commercial ELISA kits in accordance with the manufacturer’s instructions.
2.8 Histopathological evaluation of lung injury
The lungs were fixed for histological examination by instilling 0.5 mL of 10% neutral formalin through the trachea. Following fixation, the lungs were embedded in paraffin, and 5 μm sections were prepared for staining with Hematoxylin and Eosin (H&E). Histopathological analysis was conducted in a blinded manner by two independent pathologists. Assessment of acute lung injury was performed using a scoring system ranging from 0 to 2, as described in a previous study (; ). This scoring system evaluated parameters such as neutrophil presence in the alveolar and interstitial spaces, hyaline membrane formation, proteinaceous debris in airspaces, and septal thickening. A lung injury score was calculated by summing the scores of each parameter, which were then normalized to the number of fields evaluated. Three representative fields per slide were assessed in 20 high-power fields (HPF) by blinded reviewers using light microscopy at ×400 magnification.
2.9 In vivo measurement of luciferase gene expression by bioluminescence imaging with HLL mice
HIV-LTR/Luciferase (HLL) mice are genetically modified mice that are used to study the regulation of gene expression IVIS, particularly in response to NF-κB-mediated signaling, as luciferase activity can serve as a reporter for the activation of this pathway (). All bioluminescent data were collected and analyzed using in vivo Imaging Systems (IVIS) at Upstate medical university core research facilities.
2.10 Statistical analysis
The data were expressed as either mean ± SEM or median ± interquartile range following tests for normal distribution using SPSS 22 (SPSS, Chicago, United States). The sample size for each experimental group (n = 3–7) is indicated in the figure legend. Group differences were assessed using either one-way analysis of variance (one-way ANOVA) with Bonferroni’s multiple comparisons test (for normally distributed data) or Kruskal-Wallis test with Dunn’s multiple comparison test (for non-normally distributed data). Statistical significance was considered at P < 0.05. All data were obtained from three or more independent experiments.
3 Results
3.1 In vitro characterization of SsnB nanoformulation
Given the ultra flat aromatic structure of SsnB, we have screened our telodendrimers with aromatic building blocks as reported in our previous study () for SsnB encapsulation. Majority of TD nanocarriers fail to encapsulate SsnB, either for poor loading capacity or stability. As a result, PEG5kCA4Rf4 showed a stable SsnB loading, owing to the aromatic riboflavin building block. In addition, both cholic acid (CA) and riboflavin are amphiphilic, which dramatically stabilize drug loading and nanoparticle stability. As shown in Figure 1A, nSsnB has a uniform and small particle size around 17 nm, which is stable upon storage for weeks. Although SsnB was reported to be a potent TLR4/MD2 inhibitor, it was also shown to have anticancer () and antiangiogenic () activity. Indeed, free SsnB showed significant cytotoxicity upon murine macrophage cell line Raw 264.7 in cell culture with an IC50 of 28 ng/mL (Figure 2B), which is significantly reduced by nSsnB for about 500 fold to 11.4 ug/mL. At the same time, free SsnB has very high hemolytic properties in the in vitro whole blood incubation with almost instant hemolysis after 30 min incubation at 10 ug/mL. While nSsnB is safe without significant hemolysis even overnight incubation at 200 ug/mL (Figure 1C).
FIGURE 1
FIGURE 2
We further examined the anti-inflammatory effect of nSsnB in immune cell culture (RAW264.7) in the presence of LPS co-incubation. LPS significantly induced cytokine productions in the culture medium as detected by ELISA, e.g., TNF-α (Figure 2A) and IL-6 (Figure 2B), in comparison to the control. The nSsnB significantly inhibited cytokine productions induced by LPS. And it was shown that nSsnB does not have an immunostimulatory effect without cytokine induction. We further examined the activation of NF-κB in immune cells with Western blot assay. As shown in Figure 2C, the phosphorylated NF-κB P65 (p-NF-κB P65) (P < 0.05 vs. Control) induced by LPS can be effectively inhibited by nSsnB. While nSsnB had no effects on this inflammatory signaling in the comparison to the control group. These results clearly demonstrated that nSsnB possesses an anti-inflammatory effect by inhibiting the LPS-TLR-4/NF-κB pathway.
3.2 Effects of nSsnB on LPS-induced systemic inflammation and ALI
Assessment of the neutrophil-to-lymphocyte ratio (NLR) in blood during LPS-induced lung injury permits investigation of the inflammatory response and immune cell dynamics. By measuring changes in NLR, we can gain insights into the balance between pro-inflammatory (neutrophils) and anti-inflammatory (lymphocytes) responses in the blood circulation following exposure to LPS. The LPS-induced increase in NLR was attenuated by nSsnB (Figure 3A). Consistent with these findings, the LPS-induced increases in plasma TNF-α (Figure 3B) and IL-6 (Figure 3C) were both ameliorated by prophylactic nSsnB administration. Collectively these findings suggest that prophylactic nSsnB ameliorates LPS-induced systemic inflammation.
FIGURE 3
We measured inflammatory cytokine levels in BALF as an indicator if lung inflammation and total BALF protein as an indicator of increased vascular permeability in ALI. The LPS-induced increase in BALF TNF-α (Figure 3D) and IL-6 (Figure 3E) were significantly reduced by nSsnB (P < 0.05, LPS vs. LPS/nSsnB). Likewise, the increased BALF protein levels observed in LPS-treated mice were significantly reduced by prophylactic nSsnB (Figure 3F). Collectively these finding suggests nSsnB attenuates both systemic and pulmonary inflammation in this model.
3.3 BALF cytology
Lung injury and inflammation are characterized by increased leukocytes in the BALF. Hema-3 staining was used for cytological analysis of BALF (Figure 4A). Neutrophils (Figure 4B1) and macrophages (Figure 4B2) were both increased in BALF from LPS-treated mice. In contrast, pretreatment with nSsnB significantly reduced both Neutrophils and macrophages in the LPS/nSsnB group (P < 0.05, LPS vs. LPS/nSsnB). The reductions in BALF leukocytes observed in this experiment support the anti-inflammatory effects of nSsnB on LPS-induced lung inflammation and injury.
FIGURE 4
3.4 Analysis of lung histology in LPS-induced ALI in C57BL/6 mice
Analysis of lung histology is critical to assessing the severity of lung injury, validating animal models, and evaluating potential therapies. LPS-induced lung injury is characterized by polymorphonuclear neutrophils (PMNs) infiltration, alveolar hemorrhage, edema, and the formation of hyaline membranes. Pre-treatment with nSsnB mitigated histological lung injury (Figure 5A) and reduced the lung injury score (Figure 5B) in LPS-induced lung injury (P < 0.05, LPS vs. LPS/nSsnB). The histological findings support the therapeutic efficacy of prophylactic nSsnB in attenuating LPS-induced lung injury.
FIGURE 5
3.5 Pulmonary activation of MyD88 and NF-κB
Myeloid Differentiation Primary Response 88 (MyD88) and Nuclear Factor-kappa B (NF-kB) are crucial components of the Toll-like receptor (TLR) signaling pathway, especially in the context of TLR-4 activation. LPS significantly increased the pulmonary levels MyD88 (Figure 6A) and p-NF-κB P65 (Figure 6B) in C57BL/6 mice (P < 0.05 vs. Control). However, pretreatment with nSsnB significantly reduced the LPS-induced increases in both MyD88 and p-NF-κB P65 (P < 0.05 vs. LPS). LPS-induced activation of NF-κB p65 drives the transcription of pro-inflammatory cytokines, including TNF-α (Figure 6C) and IL-6 (Figure 6D). Our results demonstrate that the elevated levels of TNF-α and IL-6 in lung tissue were significantly attenuated by nSsnB treatment. We also examined pulmonary NF-κB activation using HLL mice to investigate the effects of LPS/nSsnB on NF-κB signaling in vivo (Figure 6E). The signal intensity was significantly elevated in the HLL LPS-treated mice compared to controls. As expected, pretreatment with nSsnB markedly reduced the LPS-induced signal enhancement. Overall, our in vivo and in vitro data validate SsnB as an inhibitor of TLR-2/4 signaling by blocking MyD88 and NF-κB, leading to reductions in inflammation and lung injury.
FIGURE 6
4 Discussion
ARDS is a potentially life-threatening complication of sepsis, severe trauma (indirect), pneumonia, aspiration of gastric contents, or inhalation injuries (direct). Rapidly progressive respiratory failure due to ARDS accounts for 10% of ICU admissions and has a mortality rate of 40% in severe cases (). Although supportive care including antibiotics, vasopressors, mechanical ventilation and renal replacement therapy improves outcomes, many patients develop multiple organ failure despite these aggressive treatments. Although inflammation is part of the normal host response to sepsis, severe systemic inflammation or an exaggerated inflammatory response are felt to be important in the pathogenesis of ARDS and multiple organ failure. The current study examines the anti-inflammatory effects of prophylactic nSsnB on inflammation in cultured macrophages and LPS-induced lung injury in mice. Recent studies suggested nanomedicines have been applied in respiratory diseases treatment, like chronic obstructive pulmonary disease and asthma (; ; ; ; ). SsnB is a flat aromatic molecule with poor solubility in water as well as many organic solvents. DMSO is needed to dissolve it for loading and bioactivity studies. We purposely introduce flat aromatic riboflavin into telodendrimer PEG5kCA4Rf4 to increase molecular interaction with SsnB for efficient encapsulation. In addition, the facial amphiphilic cholic acid (CA) was introduced in TD to further stabilize SsnB encapsulation by reducing the surface energy between aqueous shell and hydrophobic core of nanoparticle. As a result, the nano-formulation of SsnB used in our study (nSsnB) enhances its water solubility for feasible in vivo application.
In previous studies, SsnB was solubilized in dimethyl sulfoxide (DMSO) or polyethylene glycol, with concentrations significantly higher than those used in our study (0.625 mg/kg for mouse). Administration routes were predominantly oral (300 mg/kg for animal study) () or via intraperitoneal injection (3–9 mg/kg for animal study) (; ; ; ; ). Notably, pretreatment was conducted over a treatment period ranging from 2 to 28 days. To facilitate comparison with prior research, our current study maintained the practice of administering the nSsnB before lung injury but differed by using a single dose via intratracheal delivery. Despite lower doses and intratracheal delivery, our data provide evidence that nanoformulated SsnB has significant anti-inflammatory effects and attenuates LPS-induced lung injury.
The toxicity and safety profile of SsnB have been documented in prior investigations (). Following intraperitoneal injection of different doses of SsnB (dissolved in DMSO), mice were monitored for 6 days. None of the mice, even those administered the highest dose of SsnB (500 mg/kg), exhibited any evident abnormalities or fatalities. Additionally, histological examination did not reveal any discernible alterations in organs and tissues, including the lung, liver, spleen, and intestine (). Our results showed that both the nanoformulation of SsnB and polymer alone demonstrated no impact on cell viability in RAW264.7 cells. These data suggest our nSsnB preparation is safe for use within the dose range used in our experiments.
Our results provide evidence that nSsnB mitigates inflammation in cultured macrophages by attenuating NF-κB activation and cytokine production. nSsnB also attenuates LPS-induced lung injury by attenuating activation of the TLR-4/MyD88/NF-κB signaling pathway. When TLR-4 is activated, MyD88 (an adaptor protein) is recruited to the TLR cytoplasmic domain, forming a signaling complex that activates downstream signaling cascades. The MyD88-dependent signaling pathway phosphorylates and activates NF-κB, a transcription factor that stimulates production of inflammatory cytokines and chemokines. The ability of nSsnB to attenuate LPS-induced increases in pulmonary MyD88 levels, phosphorylated NF-κB levels, inflammatory cytokine production and NF-κB activated luminescence in LPS-treated mice is consistent with SsnB’s ability to block TLR mediated inflammation.
These results not only illustrate the therapeutic potential of inhibiting TLR-4/MyD88/NF-κB pathways in treating ALI/ARDS via intratracheal delivery of nano-formulated SsnB, but also affirm the role of SsnB as a TLR-4 inhibitor.
Our results are consistent with others showing SsnB is a selective TLR-4 antagonist and inhibits intracellular events in TLR-4 signaling (). SsnB has also been shown to attenuate TLR-4-mediated NF-κB activation in a dose-dependent manner, inhibit recruitment of MyD88 to TLR-4 and suppresses LPS-induced increases in TNF-α and IL-1β expression (). These studies also showed that pretreatment with SsnB significantly mitigated lung pathology induced by LPS (). Our findings that nSsnB reduces systemic and pulmonary inflammation, capillary leak and histologic lung injury are consistent with those of (. Our findings add to the growing evidence that the interaction between SsnB and TLR-4 has the capacity to modulate inflammation across diverse conditions, highlighting its potential in the development of novel therapeutic approaches (). Literature mining and network analysis unveiled that SsnB targets TLR-4 and MyD88-NF-κB-IL-1β/IL-6/TNF-α pathways, which are significant therapeutic targets in inflammatory diseases (). Recent studies suggest TLR-4 is emerging as a therapeutic target for treating respiratory and neurological complications associated with SARS-CoV-2 infection (). Furthermore, it has been suggested that SARS-CoV-2 may bind to and activate TLR4, resulting in increased ACE2 expression, thereby facilitating viral entry and contributing to hyperinflammation ().
In summary, we report a novel nano-formulation of SsnB which significantly enhances its bioavailability. Prophylactic inhalation of aerosolized nSsnB effectively attenuates LPS-induced inflammation and lung injury by suppressing the MyD88/NF-κB anti-inflammatory pathway. The underlying mechanism and associated signaling pathways are illustrated in detail in Figure 7. While these experimental studies in murine LPS-induced ARDS are promising, it's crucial to acknowledge that findings in animal models may not always directly correlate with human responses. Interspecies variations in lung anatomy, physiology, and immune responses can hinder full reproducibility of results. An additional limitation is that our study omitted measurements of drug pharmacokinetics and tissue biodistribution, although the pharmacokinetics and bioavailability of SsnB have been examined in previous studies involving rats (). Additional studies will be needed to further address these issues.
FIGURE 7
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The animal study was approved by Institutional Animal Care and Use Committee of SUNY Upstate Medical University. The study was conducted in accordance with the local legislation and institutional requirements.
Author contributions
QM: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Software, Validation, Writing – original draft, Writing – review and editing, Project administration. XW: Data curation, Formal Analysis, Investigation, Software, Writing – review and editing. DG: Investigation, Writing – original draft, Data curation, Methodology, Writing – review and editing. GZ: Investigation, Methodology, Writing – review and editing. CS: Investigation, Data curation, Resources, Writing – review and editing. AN: Validation, Writing – original draft. XY: Investigation, Methodology, Writing – review and editing. JL: Conceptualization, Funding acquisition, Supervision, Validation, Visualization, Writing – original draft, Writing – review and editing. RC: Conceptualization, Funding acquisition, Methodology, Project administration, Resources, Supervision, Visualization, Writing – review and editing, Writing – original draft, Validation.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. NIH/NIGMS R35GM149321 (JL).
Acknowledgments
We thank Dr. Jennifer Moffat in providing the In Vivo Imaging System (IVIS) for imaging studies.
Conflict of interest
The authors declare that the research was conducted without any commercial or financial affiliations that might present a conflict of interest.
The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2025.1532391/full#supplementary-material
References
1
AboudounyaM. M.HeadsR. J. (2021). COVID-19 and toll-like receptor 4 (TLR4): SARS-CoV-2 may bind and activate TLR4 to increase ACE2 expression, facilitating entry and causing hyperinflammation. Mediat. Inflamm.2021, 8874339. 10.1155/2021/8874339
2
AfshariA.BrokJ.MollerA. M.WetterslevJ. (2011). Inhaled nitric oxide for acute respiratory distress syndrome and acute lung injury in adults and children: a systematic review with meta-analysis and trial sequential analysis. Anesth. Analg.112, 1411–1421. 10.1213/ANE.0b013e31820bd185
3
AfzalO.AltamimiA. S. A.NadeemM. S.AlzareaS. I.AlmalkiW. H.TariqA.et al (2022). Nanoparticles in drug delivery: from history to therapeutic applications. Nanomater. (Basel)12, 4494. 10.3390/nano12244494
4
AroraS.AhmadS.IrshadR.GoyalY.RafatS.SiddiquiN.et al (2019). TLRs in pulmonary diseases. Life Sci.233, 116671. 10.1016/j.lfs.2019.116671
5
BanavasiH.NguyenP.OsmanH.SoubaniA. O. (2021). Management of ARDS - what works and what does not. Am. J. Med. Sci.362, 13–23. 10.1016/j.amjms.2020.12.019
6
BatemanH. R.LiangQ.-L.FanD.RodríguezV. E. M.LessnerS. M. (2013). Sparstolonin B inhibits pro-angiogenic functions and blocks cell cycle progression in endothelial cells. PLoS ONE8, e70500. 10.1371/journal.pone.0070500
7
BlackwellT. S.YullF. E.ChenC. L.VenkatakrishnanA.BlackwellT. R.HicksD. J.et al (2000). Multiorgan nuclear factor kappa B activation in a transgenic mouse model of systemic inflammation. Am. J. Respir. Crit. Care Med.162, 1095–1101. 10.1164/ajrccm.162.3.9906129
8
Brun-BuissonC.RichardJ. C.MercatA.ThiebautA. C.BrochardL.GroupR.-S. A. H. N. V. R. (2011). Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med.183, 1200–1206. 10.1164/rccm.201101-0135OC
9
CepkovaM.MatthayM. A. (2006). Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome. J. Intensive Care Med.21, 119–143. 10.1177/0885066606287045
10
ChassinC.PicardeauM.GoujonJ. M.BourhyP.QuellardN.DarcheS.et al (2009). TLR4-and TLR2-mediated B cell responses control the clearance of the bacterial pathogen, Leptospira interrogans. J. Immunol.183, 2669–2677. 10.4049/jimmunol.0900506
11
DattaroyD.SethR. K.DasS.AlhassonF.ChandrashekaranV.MichelottiG.et al (2016). Sparstolonin B attenuates early liver inflammation in experimental NASH by modulating TLR4 trafficking in lipid rafts via NADPH oxidase activation. Am. J. Physiol. Gastrointest. Liver Physiol.310, G510–G525. 10.1152/ajpgi.00259.2015
12
DattaroyD.SethR. K.SarkarS.KimonoD.AlbadraniM.ChandrashekaranV.et al (2018). Sparstolonin B (SsnB) attenuates liver fibrosis via a parallel conjugate pathway involving P53-P21 axis, TGF-beta signaling and focal adhesion that is TLR4 dependent. Eur. J. Pharmacol.841, 33–48. 10.1016/j.ejphar.2018.08.040
13
DiamondM.PenistonH. L.SanghaviD. K.MahapatraS.DoerrC. (2025). “Acute respiratory distress syndrome (nursing),” in StatPearls. Treasure Island (FL): StatPearls Publishing.
14
FanH.WangY.ZhaoK.SuL.DengC.HuangJ.et al (2023). Incomplete knockdown of MyD88 inhibits LPS-induced lung injury and lung fibrosis in a mouse model. Inflammation46, 2276–2288. 10.1007/s10753-023-01877-4
15
GuoD.ShiC.SuoL.JiX.YueH.YuanD.et al (2024). “Click” amphotericin B in prodrug nanoformulations for enhanced systemic fungemia treatment. J. Control. Release370, 626–642. 10.1016/j.jconrel.2024.05.003
16
GuoD.ShiC.WangL.JiX.ZhangS.LuoJ. (2020). A rationally designed micellar nanocarrier for the delivery of hydrophilic methotrexate in psoriasis treatment. ACS Appl. bio Mater.3, 4832–4846. 10.1021/acsabm.0c00342
17
GuoD.ShiC.WangX.WangL.ZhangS.LuoJ. (2017). Riboflavin-containing telodendrimer nanocarriers for efficient doxorubicin delivery: high loading capacity, increased stability, and improved anticancer efficacy. Biomaterials141, 161–175. 10.1016/j.biomaterials.2017.06.041
18
HuangQ.LeY.LiS.BianY. (2024). Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS). Respir. Res.25, 30. 10.1186/s12931-024-02678-5
19
JiangD.LiangJ.FanJ.YuS.ChenS.LuoY.et al (2005). Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat. Med.11, 1173–1179. 10.1038/nm1315
20
JiangD.LiangJ.LiY.NobleP. W. (2006). The role of Toll-like receptors in non-infectious lung injury. Cell Res.16, 693–701. 10.1038/sj.cr.7310085
21
KaushikD.BhandariR.KuhadA. (2021). TLR4 as a therapeutic target for respiratory and neurological complications of SARS-CoV-2. Expert Opin. Ther. Targets25, 491–508. 10.1080/14728222.2021.1918103
22
KovachM. A.StandifordT. J. (2011). Toll like receptors in diseases of the lung. Int. Immunopharmacol.11, 1399–1406. 10.1016/j.intimp.2011.05.013
23
LiangQ.DongS.LeiL.LiuJ.ZhangJ.LiJ.et al (2015). Protective effects of Sparstolonin B, a selective TLR2 and TLR4 antagonist, on mouse endotoxin shock. Cytokine75, 302–309. 10.1016/j.cyto.2014.12.003
24
LiangQ.WuQ.JiangJ.DuanJ.WangC.SmithM. D.et al (2011). Characterization of sparstolonin B, a Chinese herb-derived compound, as a selective Toll-like receptor antagonist with potent anti-inflammatory properties. J. Biol. Chem.286, 26470–26479. 10.1074/jbc.M111.227934
25
LiuS.HuJ.ShiC.SunL.YanW.SongY. (2021). Sparstolonin B exerts beneficial effects on prostate cancer by acting on the reactive oxygen species-mediated PI3K/AKT pathway. J. Cell Mol. Med.25, 5511–5524. 10.1111/jcmm.16560
26
MaH.XieC.HeG.ChenZ.LuH.WuH.et al (2022). Sparstolonin B suppresses free fatty acid palmitate-induced chondrocyte inflammation and mitigates post-traumatic arthritis in obese mice. J. Cell Mol. Med.26, 725–735. 10.1111/jcmm.17099
27
Matute-BelloG.DowneyG.MooreB. B.GroshongS. D.MatthayM. A.SlutskyA. S.et al (2001). An official American thoracic society workshop report: features and measurements of experimental acute lung injury in animals. Am. J. Respir. Cell Mol. Biol.44, 725–738. 10.1165/rcmb.2009-0210st
28
MedzhitovR. (2001). Toll-like receptors and innate immunity. Nat. Rev. Immunol.1, 135–145. 10.1038/35100529
29
MengQ.MaJ.SuoL.PruekprasertN.ChakrapaniP.CooneyR. N. (2023). Galantamine improves glycemic control and diabetic nephropathy in Lepr(db/db) mice. Sci. Rep.13, 15544. 10.1038/s41598-023-42665-2
30
MengQ.WangX.GuoD.ShiC.GuR.MaJ.et al (2022). Nano-chemically modified tetracycline-3 (nCMT-3) attenuates acute lung injury via blocking sTREM-1 release and NLRP3 inflammasome activation. Shock57, 749–758. 10.1097/SHK.0000000000001927
31
MengQ.WinstonT.MaJ.SongY.WangC.YangJ.et al (2024). Induced pluripotent stem cell-derived mesenchymal stem cells-derived extracellular vesicles attenuate lps-induced lung injury and endotoxemia in mice. Shock62, 294–303. 10.1097/SHK.0000000000002381
32
MeyerN. J.GattinoniL.CalfeeC. S. (2021). Acute respiratory distress syndrome. Lancet398, 622–637. 10.1016/S0140-6736(21)00439-6
33
MukherjeeS.KarmakarS.BabuS. P. (2016). TLR2 and TLR4 mediated host immune responses in major infectious diseases: a review. Braz J. Infect. Dis.20, 193–204. 10.1016/j.bjid.2015.10.011
34
NieL.CaiS. Y.ShaoJ. Z.ChenJ. (2018). Toll-like receptors, associated biological roles, and signaling networks in non-mammals. Front. Immunol.9, 1523. 10.3389/fimmu.2018.01523
35
Ortiz-MunozG.LooneyM. R. (2015). Non-invasive intratracheal instillation in mice. Bio Protoc.5, e1504. 10.21769/bioprotoc.1504
36
PandeyJ.DubeyR.KateA.PrasadB.SinhaA.MishraM. S. (2022). Nanomedicines: a focus on nanomaterials as drug delivery system with current trends and future advancement. Drug Res. (Stuttg)72, 355–366. 10.1055/a-1824-4619
37
PrakashS. (2023). Nano-based drug delivery system for therapeutics: a comprehensive review. Biomed. Phys. Eng. Express9, 052002. 10.1088/2057-1976/acedb2
38
PrasannaP.RatheeS.UpadhyayA.SulakshanaS. (2021). Nanotherapeutics in the treatment of acute respiratory distress syndrome. Life Sci.276, 119428. 10.1016/j.lfs.2021.119428
39
RamjiH. F.HafizM.AltaqH. H.HussainS. T.ChaudryF. (2023). Acute respiratory distress syndrome; A review of recent updates and a glance into the future. Diagn. (Basel)13, 1528. 10.3390/diagnostics13091528
40
SadikotR. T.KolanjiyilA. V.KleinstreuerC.RubinsteinI. (2017). Nanomedicine for treatment of acute lung injury and acute respiratory distress syndrome. Biomed. Hub.2, 1–12. 10.1159/000477086
41
ShiC.GuoD.XiaoK.WangX.WangL.LuoJ. (2015). A drug-specific nanocarrier design for efficient anticancer therapy. Nat. Commun.6, 7449. 10.1038/ncomms8449
42
ShireyK. A.LaiW.ScottA. J.LipskyM.MistryP.PletnevaL. M.et al (2013). The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature497, 498–502. 10.1038/nature12118
43
TakedaK.AkiraS. (2005). Toll-like receptors in innate immunity. Int. Immunol.17, 1–14. 10.1093/intimm/dxh186
44
WangL.ShiC.WangX.GuoD.DuncanT. M.LuoJ. (2019). Zwitterionic Janus Dendrimer with distinct functional disparity for enhanced protein delivery. Biomaterials215, 119233. 10.1016/j.biomaterials.2019.119233
45
WangY.JiangS.XiaoJ.LiangQ.TangM. (2018). Sparstolonin B improves neurological outcomes following intracerebral hemorrhage in mice. Exp. Ther. Med.15, 5436–5442. 10.3892/etm.2018.6092
46
YangR.LiuQ.WangD.ZhaoZ.SuZ.FanD.et al (2024). The toll-like receptor-2/4 antagonist, sparstolonin B, and inflammatory diseases: a literature mining and network analysis. Cardiovasc Drugs Ther. 10.1007/s10557-023-07535-z
47
YepuriN.DhawanR.CooneyM.PruekprasertN.MengQ.CooneyR. N. (2019). Sparstolonin B: a unique anti-inflammatory agent. Shock52, 568–576. 10.1097/SHK.0000000000001326
48
YuanJ.ZhangX.ZhuR.CuiZ.HuW. (2018). Sparstolonin B attenuates spinal cord injury-induced inflammation in rats by modulating TLR4-trafficking. Mol. Med. Rep.17, 6016–6022. 10.3892/mmr.2018.8561
49
ZhangJ.GuoY.MakM.TaoZ. (2024). Translational medicine for acute lung injury. J. Transl. Med.22, 25. 10.1186/s12967-023-04828-7
50
ZouN. S.LiangQ. L.LiP.LiuJ.LiuX.KangA.et al (2015). Determination of sparstolonin B by ultra-high performance liquid chromatography coupled with triple quadrupole mass spectrometry: application to pharmacokinetic study of sparstolonin B in rat plasma. Biomed. Chromatogr.29, 1486–1491. 10.1002/bmc.3447
Summary
Keywords
sparstolonin B (nSsnB), LPS, ALI/ARDS, TLR-4, NF-κB, inflammation, nanomedicine
Citation
Meng Q, Wang X, Guo D, Zhang G, Shi C, Novak A, Yang X, Luo J and Cooney RN (2025) Sparstolonin B nano-formulation attenuates LPS-induced lung injury. Front. Pharmacol. 16:1532391. doi: 10.3389/fphar.2025.1532391
Received
21 November 2024
Accepted
25 March 2025
Published
08 April 2025
Volume
16 - 2025
Edited by
Jadranka Milosevic, Captis Diagnostics Inc., United States
Reviewed by
Nagaraju Marka, UCONN Health, United States
Amit Kumar, University of Vermont, United States
Updates
Copyright
© 2025 Meng, Wang, Guo, Zhang, Shi, Novak, Yang, Luo and Cooney.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Juntao Luo, Luoj@upstate.edu; Robert N. Cooney, cooneyr@upstate.edu
† These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.